Kyowa Hakko Kirin completes biopharmaceutical API facility at Takasaki

Published: 9-Apr-2014
Manufacturing Ingredients Finance Pharmaceutical

Will contain one of the largest recombinant animal cell bioreactors in Japan

Japanese pharmaceutical company Kyowa Hakko Kirin has completed construction of a GMP biopharmaceutical API manufacturing facility at its Takasaki plant in an investment of approximately JPY6bn (€43m; US$59m).

The 3,892m2 four-storey HA4 facility contains one of the largest bioreactors for recombinant animal cells (12,000L) in Japan, as well as a purification facility with a large column.

The company says the new bioreactor will enable it to offer large scale and stable manufacturing of high-quality pharmaceutical ingredients.

Operations will commence at the new facility in the first half of 2016.

See more

You may also like

Finance

Kyowa partners with Bora Pharmaceuticals for generic filing in Japan

Read more
This project will coordinate is hoped to increase the visibility of Taiwan’s pharmaceutical capabilities, Bora says

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. TekniPlex Healthcare to showcase expanded capacity and sustainability solutions at Pharmapack Company highlights EU-based advancements in injection blow molding, multilayer blown films, and sustainable blister packaging
  4. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Finance

Kyowa partners with Bora Pharmaceuticals for generic filing in Japan

This project will coordinate is hoped to increase the visibility of Taiwan’s pharmaceutical capabilities, Bora says
Regulatory

Ultragenyx and Kyowa Kirin announce MAA for KRN23 accepted for review by EMA

Ultragenyx Pharmaceutical and Kyowa Kirin International, a wholly owned subsidiary of Kyowa Hakko Kirin, has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) for KRN23 for the treatment of X-linked hypophosphatemia (XLH)
Manufacturing

Fujifilm Kyowa Kirin Biologics starts operations

The jv between Fujifilm and Kyowa Hakko Kirin will develop, manufacture and sell biosimilars
Manufacturing

Fujifilm and Kyowa Hakko Kirin set up biosimilar jv

To start in spring 2012
Ingredients

Lonza and Kyowa Hakko extend strategic collaboration

<p>Lonza, of Switzerland, is to license its GS Gene Expression System (GS: glutamine synthetase) to Tokyo-based pharma and biotech company Kyowa Hakko and its US subsidiary BioWa Inc. </p>
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

How CDMOs can set a new gold standard when it comes to going green

Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards positive change, reports Tim Lowery, President of JSR Life Sciences and CEO, KBI Biopharma
Finance

Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China

New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
Subscribe now